A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Public ClinicalTrials.gov record NCT05455320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Study identification
- NCT ID
- NCT05455320
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 864 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2022 (Actual)
- Primary completion
- Jul 30, 2027 (Estimated)
- Completion
- May 25, 2028 (Estimated)
- Last update posted
- Sep 25, 2026
2022 – 2028
United States locations
- U.S. sites
- 40
- U.S. states
- 25
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| Norwalk Hospital-oncology | Norwalk | Connecticut | 06850 | — |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| George Washington University | Washington D.C. | District of Columbia | 20037 | — |
| Memorial Healthcare System | Hollywood | Florida | 33021 | — |
| University of Miami Health System | Miami | Florida | 33136 | — |
| University Of Illinois | Chicago | Illinois | 60612 | — |
| University of Kansas | Westwood | Kansas | 66205 | — |
| Tulane University Hospital & Clinics | New Orleans | Louisiana | 70112 | — |
| Ochsner Health System | New Orleans | Louisiana | 70121-2429 | — |
| Johns Hopkins University | Baltimore | Maryland | 21205 | — |
| Massachusetts General | Boston | Massachusetts | 02114 | — |
| Boston University Medical Center | Boston | Massachusetts | 02118 | — |
| University of Massachusetts Medical School | Worcester | Massachusetts | 01655 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| University Of Minnesota | Minneapolis | Minnesota | 55455 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110-1032 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Levine Cancer Institute, Carolinas HealthCare System | Charlotte | North Carolina | 28204 | — |
| Novant Health 1 | Charlotte | North Carolina | 28204 | — |
| Novant Health | Winston-Salem | North Carolina | 27103 | — |
| Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27157 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| The Ohio State University Wexner Medical Center - James Cancer Hospital | Columbus | Ohio | 43210 | — |
| OhioHealth | Columbus | Ohio | 43214 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107-4215 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425-8900 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Joe Arrington Cancer Research Treatment Center | Lubbock | Texas | 79410 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Virginia | Charlottesville | Virginia | 22903 | — |
| Virginia Commonwealth University - Massey Cancer Center | Richmond | Virginia | 23298 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 176 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05455320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05455320 live on ClinicalTrials.gov.